Observational Study of Analgesia and Cost-efficiency of Analgetic Medication Pumps (Zalviso and PCA-syringe Pump (PCA=Patient Controlled Analgesia)) After Urogenital Intervention at the Clinical Daily Routine
NCT ID: NCT03355352
Last Updated: 2017-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2017-11-01
2018-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will exactly examine, using questionaire for the patient, the medical stuff (nurses and anesthesiologist) the difference in the analgetic quality, the difference of the patients' mobility while being treated with one of the analgetic system and if there is a difference in the cost-efficiency.
We want to examine 50 Patients in each group. The studies should be finished in about one year.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients treated with conventional i.v. PCA
No interventions assigned to this group
Patients treated with Zalviso
Sufentanil
Sufentail sublingual 15ug nanopills
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sufentanil
Sufentail sublingual 15ug nanopills
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients compliant for a PCA system, and complied with the analysis of their data
Exclusion Criteria
* F10.2 dependence syndrome alcohol
* F11.2 dependence syndrome opioids
* F12.2 dependence syndrome cannabinoids
* F13.2 dependence syndrome sedatives and hypnotics
* F14.2 dependence syndrome cocaine
* F15.2 dependence syndrome coffin
* F.16.2 dependence syndrome hallucinogens
* F22 schizophrenia
* F41.1 generalized anxiety disorder
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Tuebingen, clinic of anästhesiology and intensiv care
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Barabar Schlisio, Dr. med
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
277/2017BO1
Identifier Type: -
Identifier Source: org_study_id